CI Q1 2026 Earnings Analysis

Thanks Alex. And speaking of major changes, this earnings call was pretty historic - it was CEO David Cordani's final quarterly call after 17 years leading the company. But the numbers certainly gave him a strong send-off.

What's interesting is that both of their main segments - Evernorth and Cigna Healthcare - performed above internal expectations. Evernorth earnings were slightly ahead, while Cigna Healthcare really exceeded expectations with 18% earnings growth year-over-year. The medical care ratio came in at 79.8%, which was better than their guidance of slightly below 81%.

Sure thing. Cigna made two big portfolio moves. First, they're planning to exit the individual exchange business at the end of 2026. This isn't a huge surprise - it's been a small and shrinking business for them. CEO-elect Brian Evanko said they couldn't see a clear path to scale it meaningfully within Cigna's overall size. The second move is potentially bigger - they announced a strategic review for eviCore, which handles prior authorization services for multiple health plans. This seems to be driven by the industry's progress on standardizing and automating prior authorization processes.

Exactly. Evanko outlined those three platforms clearly: Specialty and Care Services, which represents about 35% of company income and is growing 8-12% annually; Pharmacy Benefit Services at about 25% of income; and Cigna Healthcare at 40% of income. They're essentially doubling down on what's working and shedding what isn't.

Three main factors. First, solid specialty volume growth across the board. Second - and this is interesting - continued adoption of biosimilars and specialty generics. These deliver savings to patients while actually improving margins for Cigna. Third, they're getting contributions from their investment in Shields Health Solutions, which they made late last year. David Cordani specifically highlighted how they're using AI to improve biosimilar conversions. For drugs like Humira and Stelara, they're offering $0 out-of-pocket costs to patients while using AI to identify personalized conversion strategies. It's a win-win - lower costs, higher patient satisfaction, and better margins.

Right. When he takes over as CEO in July, Evanko outlined three areas of intensification: better use of data and AI for personalized care, driving toward more affordable care options, and shifting upstream into preventive care. He gave some concrete examples - like AI helping reduce customer service calls by 20-25% and predictive models that identify high-cost patients earlier, saving about $2,000 per member per year.

This is huge, Alex. The traditional pharmacy benefit model relies on rebates from drug manufacturers, but Cigna is moving to a completely transparent, rebate-free model starting in 2028. Their "Signature" model guarantees patients the lowest possible out-of-pocket costs - 30% lower than current brand drug prices with full transparency. They expect at least 50% of their pharmacy benefit members to be in this new model by end of 2028. During the Q&A, Evanko mentioned they're seeing strong early interest from clients, with retention rates in the mid-90s and some key new business wins already secured.

Well, looking at the Q&A, analysts were clearly focused on the strategic changes and the leadership transition. There were detailed questions about biosimilar adoption, the impact of portfolio reshaping, and how the new pharmacy model will roll out. The management team seemed confident about execution, especially Evanko as he prepares to take the reins. One thing that stood out was their discussion of GLP-1 drugs. They have about 12 million enrollees in their weight management programs, with coverage rates around 50% for larger employers but only 20% for smaller ones. The ongoing tension between employee demand and employer affordability for these expensive drugs is something they're actively managing.

A few key things. First, the success of that Signature pharmacy model rollout - that's a multi-billion dollar bet on transforming how pharmacy benefits work. Second, continued growth in the specialty business, particularly as more biosimilars come to market. Third, how well they execute the leadership transition and whether Evanko can deliver on his vision of becoming "the clear leader in consumer-focused and AI-enabled health services." They're also hosting an Investor Day in September, which should provide more detail on their strategy for each business segment.

This feels like a company in transition but from a position of strength. The financial results were solid across the board, they're making bold strategic moves, and they have a clear vision for the future. The leadership change adds some uncertainty, but Evanko has been with the company for nearly three decades and seems well-prepared. The big question is execution - can they successfully transform their pharmacy business while continuing to grow specialty services and maintain their health plan performance? The early signs look promising.

Absolutely. And that's a wrap on Cigna's Q1 2026 earnings. Thanks for listening to Beta Finch - we'll be back next time with another AI-powered earnings breakdown! ---